| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
|---|---|---|---|---|---|
| β2-AR agonist | |||||
| CuraCNMajor Depressive Disorder | |||||
| CuraXNAlzheimer’s disease | |||||
| α1A-AR agonist | |||||
| CuraAX Neurogenic Orthostaic Hypotension and Alzheimer’s disease | |||||
| β2-AR agonist | ||||
|---|---|---|---|---|
| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 |
| CuraCNMajor Depressive Disorder | ||||
| CuraXNAlzheimer’s disease | ||||
| α1A-AR agonist | ||||
| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 |
| CuraAX Neurogenic Orthostaic Hypotension and Alzheimer’s disease | ||||